90B Stock Overview
Operates as a cloud-native software technology company in the healthcare space. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
SOPHiA GENETICS SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.92 |
| 52 Week High | US$5.10 |
| 52 Week Low | US$2.86 |
| Beta | 0.99 |
| 1 Month Change | -2.67% |
| 3 Month Change | -13.10% |
| 1 Year Change | -27.00% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -15.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| 90B | DE Healthcare Services | DE Market | |
|---|---|---|---|
| 7D | -4.6% | 1.2% | -2.0% |
| 1Y | -27.0% | -20.4% | 6.9% |
Return vs Industry: 90B underperformed the German Healthcare Services industry which returned -20.4% over the past year.
Return vs Market: 90B underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| 90B volatility | |
|---|---|
| 90B Average Weekly Movement | 10.8% |
| Healthcare Services Industry Average Movement | 6.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 90B's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 90B's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 430 | Jurgi Camblong | www.sophiagenetics.com |
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.
SOPHiA GENETICS SA Fundamentals Summary
| 90B fundamental statistics | |
|---|---|
| Market cap | €207.58m |
| Earnings (TTM) | -€68.43m |
| Revenue (TTM) | €61.81m |
3.4x
P/S Ratio-3.0x
P/E RatioIs 90B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 90B income statement (TTM) | |
|---|---|
| Revenue | US$64.49m |
| Cost of Revenue | US$20.75m |
| Gross Profit | US$43.73m |
| Other Expenses | US$115.13m |
| Earnings | -US$71.40m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.07 |
| Gross Margin | 67.82% |
| Net Profit Margin | -110.71% |
| Debt/Equity Ratio | 11.6% |
How did 90B perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 05:09 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
SOPHiA GENETICS SA is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |
| Katie Tryhane | Credit Suisse |